{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:02:59Z","timestamp":1787241779499,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-Young2022- -0281"],"award-info":[{"award-number":["Y-Young2022- -0281"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06808-5","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T02:28:41Z","timestamp":1770258521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study"],"prefix":"10.1007","volume":"105","author":[{"given":"Yun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weida","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liye","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rober","family":"Peter Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"12","key":"6808_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013548. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"issue":"4","key":"6808_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/joim.12590","volume":"281","author":"O Landgren","year":"2017","unstructured":"Landgren O, Iskander K (2017) Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med 281(4):365\u2013382. https:\/\/doi.org\/10.1111\/joim.12590","journal-title":"J Intern Med"},{"issue":"2","key":"6808_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S et al (2016) Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 175(2):252\u2013264. https:\/\/doi.org\/10.1111\/bjh.14213","journal-title":"Br J Haematol"},{"issue":"1","key":"6808_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.seminhematol.2018.03.001","volume":"55","author":"O Landgren","year":"2018","unstructured":"Landgren O, Lu SX, Hultcrantz M (2018) MRD testing in multiple myeloma: the main future driver for modern tailored treatment. Semin Hematol 55(1):44\u201350. https:\/\/doi.org\/10.1053\/j.seminhematol.2018.03.001","journal-title":"Semin Hematol"},{"issue":"3","key":"6808_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-022-00645-1","volume":"12","author":"AH Bazarbachi","year":"2022","unstructured":"Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, Mohty M (2022) Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J 12(3):47. https:\/\/doi.org\/10.1038\/s41408-022-00645-1","journal-title":"Blood Cancer J"},{"issue":"10068","key":"6808_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s0140-6736(16)31594-x","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP et al (2017) Bortezomib with Lenalidomide and dexamethasone versus Lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389(10068):519\u2013527. https:\/\/doi.org\/10.1016\/s0140-6736(16)31594-x","journal-title":"Lancet"},{"issue":"10218","key":"6808_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/s0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A et al (2020) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395(10218):132\u2013141. https:\/\/doi.org\/10.1016\/s0140-6736(19)32956-3","journal-title":"Lancet"},{"issue":"10","key":"6808_CR8","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/s2352-3026(23)00217-x","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C et al (2023) Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 10(10):e825\u2013e837. https:\/\/doi.org\/10.1016\/s2352-3026(23)00217-x","journal-title":"Lancet Haematol"},{"issue":"11","key":"6808_CR9","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/s1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N et al (2021) Daratumumab, Lenalidomide, and dexamethasone versus Lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 22(11):1582\u20131596. https:\/\/doi.org\/10.1016\/s1470-2045(21)00466-6","journal-title":"Lancet Oncol"},{"issue":"10","key":"6808_CR10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/s1470-2045(21)00428-9","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L et al (2021) Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 22(10):1378\u20131390. https:\/\/doi.org\/10.1016\/s1470-2045(21)00428-9","journal-title":"Lancet Oncol"},{"key":"6808_CR11","doi-asserted-by":"publisher","first-page":"103504","DOI":"10.1016\/j.critrevonc.2021.103504","volume":"168","author":"S Kiss","year":"2021","unstructured":"Kiss S, Gede N, So\u00f3s A, Hegyi P, Nagy B, Imrei M et al (2021) Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis. Crit Rev Oncol Hematol 168:103504. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103504","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"6808_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M et al (2024) Daratumumab, Bortezomib, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 390(4):301\u2013313. https:\/\/doi.org\/10.1056\/NEJMoa2312054","journal-title":"N Engl J Med"},{"issue":"1","key":"6808_CR13","doi-asserted-by":"publisher","first-page":"101536","DOI":"10.1016\/j.beha.2024.101536","volume":"37","author":"F Passamonti","year":"2024","unstructured":"Passamonti F, Corrao G, Castellani G, Mora B, Maggioni G, Della Porta MG et al (2024) Using real-world evidence in haematology. Best Pract Res Clin Haematol 37(1):101536. https:\/\/doi.org\/10.1016\/j.beha.2024.101536","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"6808_CR14","doi-asserted-by":"publisher","first-page":"101523","DOI":"10.1016\/j.beha.2023.101523","volume":"36","author":"RP Gale","year":"2023","unstructured":"Gale RP, Zhang MJ, Lazarus HM (2023) The role of randomized controlled trials, registries, observational databases in evaluating new interventions. Best Pract Res Clin Haematol 36(4):101523. https:\/\/doi.org\/10.1016\/j.beha.2023.101523","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"6808_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/bmt.2008.447","volume":"43","author":"RP Gale","year":"2009","unstructured":"Gale RP, Eapen M, Logan B, Zhang MJ, Lazarus HM (2009) Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants? Bone Marrow Transpl 43(6):435\u2013446. https:\/\/doi.org\/10.1038\/bmt.2008.447","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"6808_CR16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1200\/jco.20.01849","volume":"39","author":"KK Patel","year":"2021","unstructured":"Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF (2021) Cost-Effectiveness of First-Line versus Second-Line use of daratumumab in Older, Transplant-Ineligible patients with multiple myeloma. J Clin Oncol 39(10):1119\u20131128. https:\/\/doi.org\/10.1200\/jco.20.01849","journal-title":"J Clin Oncol"},{"issue":"6","key":"6808_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/blood.2021015220","volume":"140","author":"C Yamamoto","year":"2022","unstructured":"Yamamoto C, Minakata D, Koyama S, Sekiguchi K, Fukui Y, Murahashi R et al (2022) Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. Blood 140(6):594\u2013607. https:\/\/doi.org\/10.1182\/blood.2021015220","journal-title":"Blood"},{"issue":"7","key":"6808_CR18","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.clinthera.2021.05.015","volume":"43","author":"S Li","year":"2021","unstructured":"Li S, Li J, Peng L, Tan C, Zeng X, Peng C et al (2021) First-line daratumumab in addition to chemotherapy for newly diagnosed multiple myeloma patients who are transplant ineligible: A Cost-Effectiveness analysis. Clin Ther 43(7):1253\u20131264e1255. https:\/\/doi.org\/10.1016\/j.clinthera.2021.05.015","journal-title":"Clin Ther"},{"key":"6808_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-024-00503-9","author":"DB Bayani","year":"2024","unstructured":"Bayani DB, Lin YC, Nagarajan C, Ooi MG, Tso ACY, Cairns J et al (2024) Modeling First-Line daratumumab use for newly diagnosed, transplant-ineligible, multiple myeloma: a cost-effectiveness and risk analysis for healthcare payers. Pharmacoecon Open. https:\/\/doi.org\/10.1007\/s41669-024-00503-9","journal-title":"Pharmacoecon Open"},{"issue":"10","key":"6808_CR20","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S et al (2017) Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31(10):2094\u20132103. https:\/\/doi.org\/10.1038\/leu.2017.29","journal-title":"Leukemia"},{"issue":"8","key":"6808_CR21","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"6808_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2023-187339","volume":"142","author":"NS Joseph","year":"2023","unstructured":"Joseph NS, Kaufman JL, Dicamillo S, Roberts D, Gupta VA, Hofmeister CC et al (2023) Comparison of response and survival outcomes in standard- and high-risk newly diagnosed transplant-eligible multiple myeloma (NDMM) patients treated with Lenalidomide, bortezomib and dexamethasone (RVD) versus daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD). Blood 142(Supplement 1):647\u2013647. https:\/\/doi.org\/10.1182\/blood-2023-187339","journal-title":"Blood"},{"issue":"15suppl","key":"6808_CR23","doi-asserted-by":"publisher","first-page":"e20024","DOI":"10.1200\/JCO.2018.36.15_suppl.e20024","volume":"36","author":"M Cavo","year":"2018","unstructured":"Cavo M, Dimopoulos MA, San-Miguel J, Jakubowiak AJ, Suzuki K, Yoon S-S et al (2018) Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE). J Clin Oncol 36(15suppl):e20024\u2013e20024. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.e20024","journal-title":"J Clin Oncol"},{"key":"6808_CR24","doi-asserted-by":"publisher","unstructured":"MongeJ, Solomon RS, Flicker K, Jayabalan DS, Guo J, Contreras J et al (2019) Institution Blood 134(Supplement1):5563\u20135563.\u00a0https:\/\/doi.org\/10.1182\/blood-2019-127697","DOI":"10.1182\/blood-2019-127697"},{"key":"6808_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106576","volume":"104","author":"S Bringhen","year":"2021","unstructured":"Bringhen S, Pour L, Vorobyev V, Vural F, Warzocha K, Benboubker L, Koh Y, Maisnar V, Karlin L, Pavic M, Campana F, Le Guennec S, Menas F, van de Velde H, Richardson PG (2021) Isatuximab plus pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leukemia research 104:106576. https:\/\/doi.org\/10.1016\/j.leukres.2021.106576","journal-title":"Leukemia research"},{"issue":"1","key":"6808_CR26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41375-021-01343-w","volume":"36","author":"T Jelinek","year":"2022","unstructured":"Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, Capkova L, Rihova L, Bezdekova R, Sevcikova S, Zidlik V, Havel M, Plonkova H, Jungova A, Minarik J, Stork M, Pour L, Pavlicek P, Spicka I, Maisnar V, Hajek R (2022) Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia 36(1):288\u2013291. https:\/\/doi.org\/10.1038\/s41375-021-01343-w","journal-title":"Leukemia"},{"issue":"1","key":"6808_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-022-01374-5","volume":"15","author":"JM Byun","year":"2022","unstructured":"Byun JM, Min CK, Kim K, Bang SM, Lee JJ, Kim JS et al (2022) Phase II trial of daratumumab with DCEP in relapsed\/refractory multiple myeloma patients with extramedullary disease. J Hematol Oncol 15(1):150. https:\/\/doi.org\/10.1186\/s13045-022-01374-5","journal-title":"J Hematol Oncol"},{"key":"6808_CR28","doi-asserted-by":"publisher","unstructured":"Choudhry P, Mariano MC, Geng H, Martin TG, 3rd, Wolf JL, Wong SW, Shah N, Wiita AP (2020) DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia 34(3):938\u2013941. https:\/\/doi.org\/10.1038\/s41375-019-0587-5","DOI":"10.1038\/s41375-019-0587-5"},{"issue":"10","key":"6808_CR29","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.3324\/haematol.2022.280660","volume":"107","author":"T Martin","year":"2022","unstructured":"Martin T, Richardson PG, Facon T, Moreau P, Perrot A, Spicka I, Bisht K, Inchausp\u00e9 M, Casca F, Mac\u00e9 S, Van de Velde H, Suzuki K (2022) Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed\/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA. Haematologica 107(10):2485\u20132491. https:\/\/doi.org\/10.3324\/haematol.2022.280660","journal-title":"Haematologica"},{"issue":"1","key":"6808_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjh.16292","volume":"189","author":"M Mohan","year":"2020","unstructured":"Mohan M, Weinhold N, Schinke C, Thanedrarajan S, Rasche L, Sawyer JR et al (2020) Daratumumab in high-risk relapsed\/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain\/amplification and GEP70 status on outcome. Br J Haematol 189(1):67\u201371. https:\/\/doi.org\/10.1111\/bjh.16292","journal-title":"Br J Haematol"},{"key":"6808_CR31","doi-asserted-by":"publisher","unstructured":"Joseph NS, Kaufman JL, Dicamillo S, Roberts D, Gupta VA, Hofmeister CC et al (2023) Comparison of response and survival outcomes in standard- and high-risk newly diagnosed transplant-eligible multiple myeloma (NDMM) patients treated with Lenalidomide, bortezomib and dexamethasone (RVD) versus Daratumumab, Lenalidomide, bortezomib and dexamethasone (D-RVD). Blood 142647. https:\/\/doi.org\/10.1182\/blood-2023-187339","DOI":"10.1182\/blood-2023-187339"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06808-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06808-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06808-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:03:36Z","timestamp":1771949016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06808-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6808"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06808-5","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the institutional review boards led by Sun Yat-sen University Cancer Center and was conducted in accordance with the Declaration of Helsinki. A waiver of informed consent was granted for anonymized data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}